Jeff Evanson
Equibles does not estimate personal net worth.
About Jeff Evanson
Outlook Therapeutics, Inc. reported in an 8-K filed September 5, 2025 that Jeff Evanson was terminated as Chief Commercial Officer, effective September 5, 2025. The proxy statement of Outlook Therapeutics, Inc. reports total compensation of $1,159,107 for Jeff Evanson in fiscal 2025, including a base salary of $420,577. Disclosed compensation is on record for 8 fiscal years.
“On September 5, 2025, Mr. Jeff Evanson stepped down as the Chief Commercial Officer of Outlook Therapeutics, Inc. (the "Company"), effective immediately (the "Effective Date").”
Affiliation history
-
Outlook Therapeutics, Inc. (OTLK)
Proxy statement
Start not stated–2025-09-05
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Outlook Therapeutics, Inc. (OTLK) | Former Chief Commercial Officer | $420,577 | $1,159,107 |
| 2024 | Outlook Therapeutics, Inc. (OTLK) | Former Chief Commercial Officer | $450,000 | $768,029 |
| 2023 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | $450,000 | $718,195 |
| 2022 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | $353,077 | $1,408,961 |
| 2021 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | — | $300,000 |
| 2020 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | — | $159,677 |
| 2019 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | — | — |
| 2018 | Outlook Therapeutics, Inc. (OTLK) | Chief Commercial Officer | — | — |